Search research articles
Contact Us
Filters
Showing results (431-440 of 463) with videos related to
Page
of 47
Sort By:
BMJ Open Gastroenterology
|
February 9, 2024
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial
Vipul Jairath, Guangyong Zou, Zhongya Wang, et al.
Gastroenterology
|
May 24, 2024
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
Stephen B Hanauer, Bruce E Sands, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 30, 2025
The EXTENT Study: Results From an International Expert Delphi Consensus to Define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn's Disease
Carolina Palmela, Joana Torres, Catarina Frias-Gomes, et al.
Journal of Crohn'S & Colitis
|
April 17, 2025
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)
Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber, et al.
Inflammatory Bowel Diseases
|
May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
Eugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 10, 2026
Per- and polyfluoroalkyl substances (PFAS) in early life is associated with childhood intestinal inflammation: analyses of three birth cohorts
Vishal Midya, Amith S Maroli, Mellissa Picker, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis
David M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Joseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Science Translational Medicine
|
October 5, 2018
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals
Mathieu Uzzan, Minami Tokuyama, Adam K Rosenstein, et al.
Gut
|
September 15, 2022
Biopsy and blood-based molecular biomarker of inflammation in IBD
Carmen Argmann, Ruixue Hou, Ryan C Ungaro, et al.
Page
of 47
Search research articles
Search
Showing results (431-440 of 463) with videos related to
Sort By:
Page
of 47
BMJ Open Gastroenterology
|
February 9, 2024
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial
Vipul Jairath, Guangyong Zou, Zhongya Wang, et al.
Gastroenterology
|
May 24, 2024
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
Stephen B Hanauer, Bruce E Sands, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 30, 2025
The EXTENT Study: Results From an International Expert Delphi Consensus to Define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn's Disease
Carolina Palmela, Joana Torres, Catarina Frias-Gomes, et al.
Journal of Crohn'S & Colitis
|
April 17, 2025
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)
Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber, et al.
Inflammatory Bowel Diseases
|
May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
Eugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 10, 2026
Per- and polyfluoroalkyl substances (PFAS) in early life is associated with childhood intestinal inflammation: analyses of three birth cohorts
Vishal Midya, Amith S Maroli, Mellissa Picker, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis
David M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Joseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Science Translational Medicine
|
October 5, 2018
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals
Mathieu Uzzan, Minami Tokuyama, Adam K Rosenstein, et al.
Gut
|
September 15, 2022
Biopsy and blood-based molecular biomarker of inflammation in IBD
Carmen Argmann, Ruixue Hou, Ryan C Ungaro, et al.
Page
of 47